Intrapulmonary Percussive Ventilation as an Airway Clearance Technique in Subjects With Chronic Obstructive Airway Diseases

Gregory Reychler PhD PT, Emilie Debier PT, Olivier Contal PhD PT, and Nicolas Audag PT

BACKGROUND: Airway clearance techniques are regularly proposed as a part of the treatment in chronic obstructive airway diseases. Intrapulmonary percussive ventilation (IPV) is used as an airway clearance technique in patients affected by excessive lung secretions. The aim of this systematic review is to summarize the physiological and clinical effects related to the use of IPV as an airway clearance technique in chronic obstructive airway diseases. METHODS: This systematic review followed the PRISMA guidelines. Randomized, controlled, comparative, and cohort studies investigating IPV as an airway clearance technique were identified and reviewed from 3 databases. Two reviewers independently assessed study quality and reviewed the selected studies. RESULTS: 278 subjects from 12 studies were included in the final analysis, with 3 diseases studied. Only one of the included studies had a sample size > 50 subjects. The main findings showed that IPV improves gas exchange during exacerbation and could reduce the hospital length of stay for patients with COPD. In subjects with cystic fibrosis, neither lung function nor other parameters were improved. CONCLUSIONS: The systematic use of IPV as an airway clearance technique in chronic obstructive airway diseases is not supported by sufficiently strong evidence to recommend routine use in this patient population. Key words: intrapulmonary percussive ventilation; airway clearance; physiotherapy; cystic fibrosis; COPD. [Respir Care 2018;63(5):620–631. © 2018 Daedalus Enterprises]

Introduction

Airway secretions are one of the pathological components of the different chronic obstructive airway diseases.

Therefore, airway clearance techniques are regularly used with patients who have these diseases. Airway clearance techniques aim to decrease airway resistance, improve gas exchange, and reduce respiratory load by improving airway clearance. While its efficiency is often debated, airway clearance techniques remain widely prescribed in the treatment of many chronic obstructive airway diseases.1–3 Conventional airway clearance techniques, including postural drainage, percussion, and vibration have been described in the early literature.4 New and different techniques derived from manual or instrumental interventions have appeared since then. These new techniques, however, are not always supported by well-designed, randomized studies.5–7

Intrapulmonary percussive ventilation (IPV) derives from high-frequency percussive ventilation, which was initially applied to treat respiratory failure after smoke inhalation or burns.8–11 It is a pressure-limited, time-cycled, high-frequency mode of ventilation that delivers sub-physiologic tidal volumes. Since its emergence, IPV has been progressively used in patients affected by excessive respiratory secretions or to treat atelectasis.12–18

In IPV, a pneumatic device (ie, a phasitron) is connected to a nebulizer. It is used to improve airway clear-
ance, to deliver medications, or to promote an adequate level of secretion hydration. This modality intermittently delivers small volumes at high frequencies, creating percussions in the lungs. A face mask, mouthpiece, endotracheal tube, or tracheostomy can be used as an interface. The pressure, frequency, and inspiratory/expiratory ratio can be determined depending on the objectives of the treatment. Even though IPV is frequently used as an airway clearance technique in various chronic obstructive airway diseases, there is a wide disparity in its use. These differences are explained by a lack of evidence regarding physiological effects, clinical effectiveness, and the settings related to specific diseases or conditions.

The aim of this systematic review is to summarize the immediate or prolonged physiological effects (eg, gas exchange, cardiorespiratory parameters, lung function, and mechanics) and clinical effects (eg, symptoms, adverse effects, and length of hospital stay) related to the use of intrapulmonary percussive ventilation as an airway clearance technique in different chronic obstructive airway diseases in stable or acute conditions.

**Methods**

**Protocol**

The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines were consulted during the stages of design, analysis, and reporting of this systematic review. According to these guidelines, the structured search, study selection, risk-of-bias assessment of individual studies, and best-evidence synthesis for relating risk-of-bias to consistency of effect sizes were included in this review. The protocol for this review has been registered in the international prospective register of systematic reviews (PROSPERO, Registration No. CRD42017068336).

**Search Strategy**

PubMed, PEDro, and Scopus online databases were screened for the primary search strategy from inception to May 2017. The key terms were obstructive, COPD, cystic fibrosis, asthma*, chronic obstructive pulmonary disease, COPD, chronic obstructive airway disease, COAD, or chronic air flow for the patient category, and intrapulmonary percussive ventilat*, IPV, or percussionnaire for the intervention category. An asterisk (*) indicates a wild card character.

The full search strategy for PubMed was adapted for other databases using terms and Medical Subject Headings combined with Boolean operators. A manual search of reference lists from the identified articles, citation tracking of included articles, and use of the PubMed related articles option completed the database searches to avoid missing relevant studies.

**Inclusion and Exclusion Criteria**

After removal of duplicates, the retrieved abstracts were reviewed critically and independently for relevance by 2 independent investigators (ED, GR). On the basis of these abstracts, research articles were included if they involved studies evaluating immediate or prolonged primary end points of physiological effects (eg, blood gas results, cardiorespiratory parameters, lung function or lung mechanics, and sputum weight) or secondary end points of clinical effects related to IPV in one of the chronic obstructive airway diseases (COPD, cystic fibrosis [CF], asthma, and bronchiectasis). They must have been written in English or French, and they must have been classified as randomized controlled studies (RCTs), cohort/case studies, or comparative studies (Table 1). Studies of children < 5 y old, regarding IPV out of the scope of airway clearance techniques, or including subjects with a restrictive disease were excluded, as were abstracts without full text. The investigators reviewed full-text articles when the inclusion or exclusion was unclear based on the title and abstract. Any disagreement about eligibility was resolved by a consensus meeting between 3 investigators (GR, OC, NA).

**Data Extraction, Study Quality Appraisal, and Risk of Bias Assessment**

Two investigators (ED, GR) extracted study details and data. Extracted data included the study design, sample
characteristics (including number of participants, age group, disease [COPD, CF, asthma, and bronchiectasis] and its severity, and inclusion/exclusion criteria of the study), protocols used (eg, device, session and treatment duration, frequency, intensity, and other settings), and outcomes. The same 2 investigators assessed the internal validity of the randomized, controlled and crossover studies using the PEDro scale and applied the quality index developed by Downs and Black for assessing methodological quality and bias for all of the reviewed studies.23,24 The Downs and Black tool, which is composed of 27 questions, was identified in a review by the Health Technology Group as one of the most appropriate tools for the evaluation of non-randomized, controlled trials in systematic reviews.24,25 Originally, the total maximum score was 32 points, but it was modified to a maximum score of 28.26 Each non-randomized controlled study was assigned a grade of excellent (24 – 28 points), good (19 – 23 points), fair (14 – 18 points), or poor (< 14 points).26

Summary Measures

The investigators considered the results of the studies when the inclusion criteria were respected. Mean comparison, adverse effects, and adherence/completion rate were reported. Results were analyzed according to the diseases of the included studies.

Results

Study Selection

A total of 109 references were retrieved in the different databases and other sources (Fig. 1). After duplicates were removed, 59 articles were screened. From this analysis, 12 studies (7 RCTs12,14,27-31) were included in the systematic review.

Characteristics of the Studies

The characteristics of the studies are described in Table 2.

Population and Inclusion Criteria. A total of 278 subjects were included, of whom 15 did not complete the proposed protocol. Only one of the included studies had a sample size > 50 subjects. The mean age of included subjects was 52.7 y. One publication did not mention the age of included subjects.32

COPD. Six studies recruited subjects with COPD (n = 178).15,27,28,31-33 Three studies were performed in ICUs during an exacerbation,7,27,33 and 2 studies were performed in stable out-patients.15,28 Two studies clearly mentioned the subjects’ characteristics at the time of inclusion.27,31 Three studies excluded tracheostomized patients,15,31,33 and 4 studies required hemodynamic stability.15,27,31,33

CF and Bronchiectasis. Four studies evaluated subjects with CF (n = 78),12,14,29,30 and 1 study investigated subjects with bronchiectasis.34 In subjects with CF, pneumothorax and hemoptysis were considered as a contraindication in all studies.12,14,29,30 Only 1 study was performed during exacerbation.30 Tracheostomy was an exclusion criterion for the study involving subjects with bronchiectasis.

Interventions. IPV was mainly compared to other airway clearance techniques, including postural drainage combined with manual percussions,27,30,34 slow expiration with glottis opened in infralateral decubitus position (ELTGOL),15,27 autogenic drainage,29 forced expiration technique and cough,15 high-frequency chest-wall compressions (HF-CWC),30 noninvasive ventilation (NIV),27,28 oscillating positive expiratory pressure (Flutter, Axcan Scandipharm, Birmingham, AL),14 or nebulization alone.29 Immediate effects were analyzed in 2 observational studies.32,33 Testa et al15 combined IPV with a pulmonary rehabilitation program.

IPV Settings. Different devices were used (IMP1, IMP2; Percussionaire, Sandpoint, ID) depending on the condi-
<table>
<thead>
<tr>
<th>Study</th>
<th>Study Design</th>
<th>Population (Mean Age)</th>
<th>Acute or Stable</th>
<th>Inclusion and Exclusion Criteria</th>
<th>Interventions (Duration) (n)</th>
<th>IPV Model and Settings</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antonaglia et al</td>
<td>RCT</td>
<td>COPD exacerbation (70 y)</td>
<td>Acute</td>
<td>Inclusion: ≤ 12 h of admission to the emergency department + f &gt; 25 breaths/min + pH ≤ 7.35 + PaCO₂ &gt; 50 mm Hg; Exclusion: Glasgow Coma Scale score &lt; 8, failure of &gt; 2 additional organs, severe hemodynamic instability, electrocardiogram instability, intubation for cardiopulmonary resuscitation</td>
<td>Control group 1: NIV with helmet (3–4 h)/SB with airway clearance (2–3 h) (20) IPV group: NIV with helmet (3–4 h)/SB with IPV via mouthpiece (2–3 h) (20) Control group 2: NIV with mask (3–4 h)/SB with airway clearance for 24 h (2–3 h) (40)</td>
<td>IPV1 25–30 min P&lt;sub&gt;aw&lt;/sub&gt; &lt; 40 cm H₂O Freq = 225 cycle/min</td>
</tr>
<tr>
<td>Homnick et al</td>
<td>RCT</td>
<td>Cystic fibrosis (11 y)</td>
<td>Stable</td>
<td>Inclusion: airway clearance techniques used at home, &gt; 5 y old, stable, out-patient, no history of pneumothorax or hemoptysis, ability to tolerate at least 2 IPV or standard airway clearance sessions per day</td>
<td>IPV group: IPV (1.25–2.5 mg albuterol/treatment) (10) Control group: CPT + aerosol (1.25–2.5 mg albuterol/treatment) (10) 5 × 30 d, ≥ 2 sessions/d</td>
<td>IPV1 20–30 min P&lt;sub&gt;aw&lt;/sub&gt; &lt; 30 cm H₂O Freq = 180–300 cycles/min</td>
</tr>
<tr>
<td>Ides et al</td>
<td>Observational</td>
<td>COPD exacerbation</td>
<td>Acute</td>
<td>Inclusion: GOLD 3 and 4 during hospitalization</td>
<td>1 session before/after IPV (5)</td>
<td>NA</td>
</tr>
<tr>
<td>Nava et al</td>
<td>RCT</td>
<td>COPD (65.2 y)</td>
<td>Stable</td>
<td>Inclusion: stable and severe, hypersecretion &lt; 10 mL/d, chronic hypercapnic respiratory failure</td>
<td>Phase 1: IPV (10) Phase 2: 2 sessions IPV + NIV (5 from Phase 1) Phase 1: 4 × 10 min IPV + 15 min SB Phase 2: 2 × 10 min IPV + 15 min SB 1 day by phase</td>
<td>IMP2 Phase 1 1.220 cm H₂O-250 cycles/min (A) 1.840 cm H₂O-250 cycles/min (B) 1.840 cm H₂O-350 cycles/min (C) 1.220 cm H₂O-350 cycles/min (D) Phase 2 (A–B) + NIV (JE = 1/2.5 and P&lt;sub&gt;aw&lt;/sub&gt; &lt; 30 cm H₂O)</td>
</tr>
<tr>
<td>Newhouse et al</td>
<td>RCT, crossover</td>
<td>Cystic fibrosis (17 y)</td>
<td>Stable</td>
<td>Exclusion: Recent hemoptysis or pneumothorax</td>
<td>1 session/d for 3 d Session 1: IPV (2.5 mg albuterol in 19.5 mL) (10) Session 2: aerosol (2.5 mg albuterol in 3.0 mL) and Flutter (10) Session 3: aerosol (2.5 mg albuterol in 3.0 mL) and conventional airway clearance (10)</td>
<td>IPV1 20 min P&lt;sub&gt;aw&lt;/sub&gt; = 10–30 cm H₂O Freq = 180–300 cycles/min</td>
</tr>
<tr>
<td>Paneroni et al</td>
<td>RCT crossover</td>
<td>Bronchiectasis (64.5 y)</td>
<td>Stable</td>
<td>Inclusion: daily sputum &gt; 20 mL, for 2 d, stable ≥ 4 d, hemodynamic stability Exclusion: tracheostomy, NIV, sensory abnormalities</td>
<td>IPV group: IPV and airway clearance (22) Control group: IPV and airway clearance + cough (22) 1 session/d for 2 d</td>
<td>IMP2 30 min P&lt;sub&gt;aw&lt;/sub&gt; (low and high) Freq = NA</td>
</tr>
<tr>
<td>Testa et al</td>
<td>Controlled</td>
<td>COPD (70.5 y)</td>
<td>Stable</td>
<td>Inclusion: Daily sputum &gt; 20 mL, for 5 d and hemodynamic stability Exclusion: Arrhythmias, hemodynamic instability, respiratory failure or the need for mechanical ventilation, sepsis, sensory abnormalities, costal fractures, skeletal muscle dysfunction, orthopedic impairment, history of recent spontaneous pneumothorax, or tracheostomy</td>
<td>IPV group: PR + conventional airway clearance + IPV (10) Control group: PR + conventional airway clearance (10) 25 min/session for 10 d</td>
<td>IPV–2C 15 min P&lt;sub&gt;aw&lt;/sub&gt; = 5–35 cm H₂O Freq = 100–300 cycles/min Low P&lt;sub&gt;aw&lt;/sub&gt;/high Freq. and high P&lt;sub&gt;aw&lt;/sub&gt;/low Freq</td>
</tr>
</tbody>
</table>

(continued)
<table>
<thead>
<tr>
<th>Study</th>
<th>Study Design</th>
<th>Population (Mean Age)</th>
<th>Acute or Stable</th>
<th>Inclusion and Exclusion Criteria</th>
<th>Interventions (Duration) (n)</th>
<th>IPV Model and Settings</th>
</tr>
</thead>
<tbody>
<tr>
<td>Van Ginderdeuren et al 29</td>
<td>RCT, crossover</td>
<td>Cystic fibrosis (22 y)</td>
<td>Stable</td>
<td>Inclusion: Stable ≥ 3 mo, ≥ 16 y, trained for IPV and AD</td>
<td>Control group: SalineNEB + AD IPV group: SalineNEB + AD (20)</td>
<td>IPV2 15 min $P_{aw} = 15-25$ cm H$_2$O Freq = 240–360 cycles/min</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Exclusion: history of atopy, allergic rhinitis, asthma, pneumothorax, or major hemoptysis</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>3 mo, ≥ 16 y, trained for IPV and AD</td>
<td>2 sessions/d for 2 d</td>
<td></td>
</tr>
<tr>
<td>Varekojis et al 30</td>
<td>RCT</td>
<td>Cystic fibrosis (24 y)</td>
<td>Acute</td>
<td>Inclusion: ≥ 12 y, hospitalized</td>
<td>IPV</td>
<td>IPV1 3 × 8 min $P_{aw} = NA$ Freq = 120–300 cycles/min</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Exclusion: Recent major hemoptysis or pneumothorax, cardiac insufficiency, rib fracture, or pregnancy</td>
<td>Postural drainage and percussions HFCWC (28) 3 times/d for 2 d by technique (6 d)</td>
<td></td>
</tr>
<tr>
<td>Vargas et al 31</td>
<td>RCT</td>
<td>COPD exacerbation (69.7 y)</td>
<td>Acute</td>
<td>Inclusion: Hospitalized in ICU, $f = 25$ breaths/min, $P_{aco}_2 &gt; 45$ mm Hg after 10 min O$_2$ delivery, $7.35 \leq \text{pH} \leq 7.38$ without metabolic acidosis</td>
<td>IPV group: IPV + standard treatment (16) Control group: standard treatment (17) 2 sessions/d (stop when $f &lt; 25$/min and $\text{pH} &gt; 7.38$) in SB</td>
<td>IPV1 30 min $P_{aw} = 5-35$ cm H$_2$O Freq = 80-650 cycles/min</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Exclusion: Intubation, hemodynamic instability, failure of &gt; 2 additional organs, tracheotomy, pneumothorax, facial deformity, or a recent history of oral, oesophageal, or gastric surgery</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Before/after IPV (25)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vargas et al 33</td>
<td>Observational</td>
<td>COPD exacerbation (63 y)</td>
<td>Acute</td>
<td>Inclusion: 1 h post-extubation, stable with $f &lt; 30$ breaths/min and $\text{pH} &gt; 7.35$</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Exclusion: Emergency intubation, hemodynamic instability, failure of &gt; 2 additional organs, tracheotomy, pneumothorax, facial deformity, or a recent history of oral, oesophageal, or gastric surgery</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**IPV** = intrapulmonary percussive ventilation  
$f$ = breathing frequency  
RCT = randomized controlled trial  
NIV = noninvasive ventilation  
SB = spontaneous breathing  
$P_{aw}$ = airway pressure  
Freq = compression frequency  
CP = cystic fibrosis  
HFCWC = high-frequency chest wall compression  
GOLD = Global Initiative for Chronic Obstructive Lung Disease  
PR = pulmonary rehabilitation  
AD = autogenic drainage  
SalineNEB = saline solution delivered by nebulizer  
SalineIPV = saline solution delivered by IPV  
CPT = chest physiotherapy  
NA = not available
IPV AND CHRONIC OBSTRUCTIVE AIRWAY DISEASES

Table 3. Quality Evaluation Using the PEDro Scale for Randomized Controlled Studies

<table>
<thead>
<tr>
<th>Study</th>
<th>Eligibility Criteria</th>
<th>Randomly Allocated</th>
<th>Concealed Allocation</th>
<th>Similar Groups at Baseline</th>
<th>Blinding of Subjects</th>
<th>Blinding of Therapists</th>
<th>Blinding of Assessors</th>
<th>Data From &gt; 85% of Subjects</th>
<th>Intention to Treat</th>
<th>Statistical Comparison</th>
<th>Measures of Variability</th>
<th>Final Score</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antonaglia et al27</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>5/10</td>
</tr>
<tr>
<td>Homnick et al12</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>4/10</td>
</tr>
<tr>
<td>Nava et al28</td>
<td>No</td>
<td>Yes</td>
<td>No</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
<td>Yes</td>
<td>Yes</td>
<td>5/10</td>
</tr>
<tr>
<td>Newhouse et al14</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>Yes</td>
<td>3/10</td>
</tr>
<tr>
<td>Paneroni et al34</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>4/10</td>
</tr>
<tr>
<td>Van Ginderdeuren et al29</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>5/10</td>
</tr>
<tr>
<td>Varekojis et al30</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>4/10</td>
</tr>
<tr>
<td>Vargas et al31</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>6/10</td>
</tr>
</tbody>
</table>

Table 4. Quality Evaluation Using the Downs and Black Quality Index for Randomized and Non-Randomized Controlled Studies

<table>
<thead>
<tr>
<th>Study</th>
<th>Reporting (11)*</th>
<th>External validity (3)*</th>
<th>Bias (7)*</th>
<th>Confounding (6)*</th>
<th>Power (1)*</th>
<th>Total (28)*</th>
<th>Grades†</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antonaglia et al27</td>
<td>8</td>
<td>3</td>
<td>5</td>
<td>5</td>
<td>0</td>
<td>21</td>
<td>Good</td>
</tr>
<tr>
<td>Homnick et al12</td>
<td>8</td>
<td>3</td>
<td>5</td>
<td>4</td>
<td>0</td>
<td>20</td>
<td>Good</td>
</tr>
<tr>
<td>Idos et al32</td>
<td>7</td>
<td>0</td>
<td>5</td>
<td>3</td>
<td>0</td>
<td>15</td>
<td>Fair</td>
</tr>
<tr>
<td>Nava et al28</td>
<td>7</td>
<td>1</td>
<td>5</td>
<td>2</td>
<td>0</td>
<td>15</td>
<td>Fair</td>
</tr>
<tr>
<td>Newhouse et al14</td>
<td>9</td>
<td>3</td>
<td>5</td>
<td>4</td>
<td>0</td>
<td>21</td>
<td>Good</td>
</tr>
<tr>
<td>Paneroni et al34</td>
<td>8</td>
<td>3</td>
<td>5</td>
<td>4</td>
<td>0</td>
<td>20</td>
<td>Good</td>
</tr>
<tr>
<td>Testa et al15</td>
<td>9</td>
<td>1</td>
<td>5</td>
<td>6</td>
<td>0</td>
<td>19</td>
<td>Fair</td>
</tr>
<tr>
<td>Van Ginderdeuren et al29</td>
<td>8</td>
<td>3</td>
<td>5</td>
<td>4</td>
<td>0</td>
<td>20</td>
<td>Good</td>
</tr>
<tr>
<td>Varekojis et al30</td>
<td>8</td>
<td>3</td>
<td>5</td>
<td>4</td>
<td>0</td>
<td>20</td>
<td>Good</td>
</tr>
<tr>
<td>Vargas et al31</td>
<td>7</td>
<td>3</td>
<td>5</td>
<td>3</td>
<td>0</td>
<td>18</td>
<td>Fair</td>
</tr>
<tr>
<td>Vargas et al33</td>
<td>9</td>
<td>3</td>
<td>5</td>
<td>4</td>
<td>0</td>
<td>22</td>
<td>Good</td>
</tr>
</tbody>
</table>

* Maximum score for each item with the Downs and Black Quality Index.
† Grading total score: Excellent (24–28 points); Good (19–23 points); Fair (14–18 points); Poor (< 14 points).

The results are reviewed in Tables 5 and 6.

Gas Exchange in COPD, CF, and Bronchiectasis. Acid–base balance was improved by IPV combined with NIV, standard treatment, or used alone during an exacerbation.27,31,33 After 1 session, PaO₂ and PaCO₂ improved during COPD exacerbation.27,31,33 but IPV was no more beneficial in stable condition than other airway clearance techniques when subjects were stable.15 After IPV combined with NIV, gas exchange was improved compared to CPT with NIV.27 Short- and long-term effects were observed on impaired gas exchange in subjects with COPD. This benefit was only found in acute conditions. Gas exchange was not used as an outcome measure in CF or in bronchiectasis.
### Table 5. Results of the Studies in Patients With COPD

<table>
<thead>
<tr>
<th>Study</th>
<th>Results</th>
</tr>
</thead>
</table>
| **Antonaglia et al**<sup>27</sup> | Drop-out 0  
Gas exchange  
IPV group after 1 session  
↑ pH (0.4%, *P < .01)  
↓ P<sub>acO<sub>2</sub> (7.5 mm Hg, *P < .01)  
↓ P<sub>acO<sub>2</sub>/FiO<sub>2</sub> (18%, *P < .01)  
IPV group vs Control group 1 and Control group 2 at discharge  
↓ P<sub>acO<sub>2</sub> (21 mm Hg, *P < .01)  
↑ P<sub>acO<sub>2</sub>/FiO<sub>2</sub> (18.6%, *P < .01)  
Control group 1 vs Control group 2: no difference |
| **Cardio-respiratory parameters** | IPV group after 1 session  
↓ Breathing frequency (14.3%, *P < .01)  
↓ Heart rate (13%, *P = .02)  
Length of ICU stay | IPV group (7 d) vs Control group 1 (7 d) and Control group 2 (10 d)  
Control group 1 = Control group 2 (*P < .01)  
Intubation | IPV group (7) = Control group 1 (7) = Control group 2 (21) (NS)  
Ventilatory assistance | IPV group (61 h) = Control group 1 (89 h) = Control group 2 (87 h) (*P < .01)  
IPV group vs Control group 1 and Control group 2; Control group 1 = Control group 2 |
| **Ides et al**<sup>32</sup> | Drop-out 0  
Gas exchange  
Lung function and mechanics | No difference after 1 session  
Satisfaction | Subjectively better after treatment |
| **Nava et al**<sup>28</sup> | Drop-out 0  
Lung function  
Phase 1:  
↑ V<sub>T</sub> (<sup>A</sup>, *P < .05; <sup>C</sup>, *P < .01; <sup>D</sup>, *P < .05)  
Phase 2:  
↑ V<sub>T</sub> (<sup>B</sup>)  
Lung mechanics | No difference in compliance and resistance in all groups  
Phase 1:  
↓ PTP<sub>di</sub> (<sup>A</sup> - <sup>B</sup>)  
Phase 2:  
↓ PTP<sub>di</sub> (<sup>A</sup> - <sup>B</sup> - NIV) |
| **Testa et al**<sup>15</sup> | Drop-out 0  
Gas exchange | IPV group:  
↑ P<sub>acO<sub>2</sub> (8.4 mm Hg, *P = .05)  
IPV group vs Control group: no difference in P<sub>acO<sub>2</sub> (*P = .81)  
Cardio-respiratory parameters | IPV group  
↑ S<sub>acO<sub>2</sub> (4.2%, *P = .02)  
↓ Dyspnea (*P = .01)  
Lung function | IPV group:  
↑ P<sub>max</sub> (<sup>P</sup> < .001) and  
↑ P<sub>max</sub> (<sup>P</sup> < .004)  
Control group:  
↑ P<sub>max</sub> (<sup>P</sup> < .02) and  
↑ P<sub>max</sub> (<sup>P</sup> < .039) |
| **Vargas et al**<sup>31</sup> | Drop-out 0  
Gas exchange | IPV group:  
↑ P<sub>acO<sub>2</sub> - P<sub>acO<sub>2</sub></sub>, ↓ P<sub>acO<sub>2</sub></sub>  
Cardio-respiratory parameters | IPV group: breathing frequency after treatment (*P < .05)  
Length of stay | IPV group vs Control group:  
↓ 14% (*P < .05)  
Worsening of exacerbation | IPV group (0%) and Control group (35.3%), *P < .05 |
| **Vargas et al**<sup>33</sup> | Drop-out 0  
Gas exchange |  
↑ pH (0.14%)  
↑ P<sub>acO<sub>2</sub> (3.8 mm Hg, *P < .05)  
↓ P<sub>acO<sub>2</sub> (2.7 mm Hg, *P < .05)  
↑ S<sub>acO<sub>2</sub> (3.3%, *P < .05)  
↓ Heart rate (5.3%, *P < .05)  
Lung function |  
↓ 30% Peak expiratory flow limitation (*P < .05)  
↓ 28.2% Airway occlusion pressure (*P < .05) |

**IPV** = intrapulmonary percussive ventilation  
**NS** = not significant  
**V<sub>T</sub>** = tidal volume  
**V<sub>E</sub>** = minute volume  
**PTP<sub>di</sub>** = diaphragmatic pressure-time product  
**P<sub>max</sub>** = maximum inspiratory pressure  
**P<sub>max</sub>** = maximum expiratory pressure
Table 6. Results of the Studies in Patients With CF and Bronchiectasis

<table>
<thead>
<tr>
<th>Study</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Homnick et al12</td>
<td><strong>Drop-out</strong> 4 (IPV group: 2, Control group: 2)</td>
</tr>
<tr>
<td></td>
<td>After treatment, no difference in both groups (IPV group and Control group):</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>FEV1 (P = .88 and P = .99)</td>
</tr>
<tr>
<td></td>
<td>FVC (P = .99 and P = .88)</td>
</tr>
<tr>
<td></td>
<td>FEF25–75% (P = .71 and P = .73)</td>
</tr>
<tr>
<td></td>
<td><strong>Length of stay</strong> No difference</td>
</tr>
<tr>
<td></td>
<td><strong>Oral or IV antibiotic use</strong> No difference between groups</td>
</tr>
<tr>
<td></td>
<td><strong>Satisfaction (IPV vs other airway clearance technique)</strong> Efficacy (75%), time-consuming (0%), independence (87.5%), comfort (62.5%)</td>
</tr>
<tr>
<td></td>
<td><strong>Complications</strong> Hemoptysis (n = 1 in IPV group)</td>
</tr>
<tr>
<td>Newhouse et al14</td>
<td><strong>Drop-out</strong> 2 (infection)</td>
</tr>
<tr>
<td></td>
<td>No change in static lung volume after 1 h and 4 h</td>
</tr>
</tbody>
</table>
|                     | IPV  
|                     | ↑ FEV1 after 1 h (P = .02)                                              |
|                     | Flutter  
|                     | ↑ FVC after 1 h (P = .02)                                               |
|                     | ↑ FEV1 after 1 h (P = .033) and 4 h (P = .048)                          |
|                     | **Sputum** No change in sputum wet weight after 1 h and 4 h             |
|                     | **Adverse effects** No                                                   |
| Paneroni et al14    | **Drop-out** 0                                                          |
|                     | IPV group  
|                     | ↓ breathing frequency (P = .02)                                         |
|                     | ↓ dyspnea (P = .04)                                                    |
|                     | ↓ heart rate (P = .002)                                                 |
|                     | S\textsubscript{O2} (NS)                                                |
|                     | IPV group vs Control group: only breathing frequency was different (P = .047) |
|                     | **Sputum** No change in volume and wet/dry weight                       |
|                     | **Satisfaction** No difference between techniques in comfort, convenience, efficacy, ease of use, and global satisfaction |
|                     | IPV group: ↓ sensation of encumbrance and ↓ discomfort (P = .03)        |
|                     | IPV group vs Control group: no difference                               |
|                     | **Adverse effects** Both groups: 27% (dry throat, nausea, and/or fatigue) |
| Van Ginderdeuren et al29 | **Drop-out** No data                                                   |
|                     | IPV group vs Contol group: no difference in S\textsubscript{O2}, heart rate, and dyspnea |
|                     | **Sputum** No difference in sputum wet weight                           |
|                     | Autogenic drainage increased sputum wet weight in both groups (P < .001) |
| Varekojis et al30    | **Drop-out** 4                                                          |
|                     | Wet weight: IPV > HFCWC (P = .035)                                      |
|                     | No difference in dry weight (P = .17)                                   |
|                     | **Satisfaction** No difference between techniques in comfort, convenience, efficacy, ease of use, and global satisfaction |
|                     | Preferred technique: 10 subjects preferred HFCWC                          |
|                     | 7 subjects preferred IPV                                                |
|                     | 7 subjects preferred postural drainage and percussion                    |

\textit{CF} = cystic fibrosis  
\textit{IPV} = intrapulmonary percussive ventilation  
\textit{FEF\textsubscript{25–75}} = forced expiratory flow between 25–75\% of vital capacity  
\textit{NS} = not significant  
\textit{HFCWC} = high-frequency chest wall compression
Cardiorespiratory Parameters, Lung Function, and Lung Mechanics in COPD, CF, and Bronchiectasis. In subjects with COPD in stable conditions and during exacerbation, all cardio-respiratory parameters, lung function, and lung mechanics decreased with IPV. Compared to spontaneous breathing, the tidal volume increase associated with IPV was related to the settings (1.220 cm H$_2$O-250 c/min, 1.220 cm H$_2$O-350 c/min, and 1.840 cm H$_2$O-350 c/min), but a reduced diaphragmatic loading was only observed for 1 setting (1.220 cm H$_2$O-250 c/min). After 1 day of treatment in stable subjects, 1 study showed an improvement in inspiratory and expiratory muscle strength.

The cardiorespiratory parameters were not modified by IPV in subjects with CF. Only dyspnea and respiratory frequency improved after 1 session of IPV in subjects with bronchiectasis. No change was observed in static or dynamic lung volume in subjects with CF. Based on these results, the benefits related to IPV in these disease states do not appear to be evident.

Sputum Weight in COPD, CF, and Bronchiectasis. Sputum was not considered as an outcome in studies evaluating the effects of IPV in subjects with COPD. All studies related to CF were short-term studies. Sputum was collected in 3 studies of subjects with CF and in 1 study of subjects with bronchiectasis. All of these studies compared IPV with other airway clearance techniques (e.g., autogenic drainage, HFCWC). Increased sputum wet weight was observed with IPV compared to HFCWC in subjects hospitalized for an exacerbation and after autogenic drainage combined with IPV compared to IPV alone in stable subjects. These short-term studies administered saline solution by nebulization simultaneously to the IPV session. However, when investigated, no difference was observed in sputum dry weight. In subjects with productive bronchiectasis, the immediate efficacy of IPV and other airway clearance techniques was not different. These results are not sufficient to make conclusions about the efficacy of IPV on sputum in patients with CF or bronchiectasis.

Length of Hospital Stay and Other Clinical Outcomes in COPD, CF, and Bronchiectasis. The length of hospital stay was reduced by IPV compared to other airway clearance techniques or to a classical medical treatment alone in 2 studies in subjects with COPD during exacerbation. In 1 study, a decrease in the need for mechanical ventilation was observed. Only 1 long-term study focused on these outcomes by comparing IPV and conventional airway clearance techniques in subjects with CF. Neither the duration of antibiotics use nor the length of hospital stay were modified by IPV in these subjects.

Satisfaction. In 1 long-term study, > 75% of subjects with CF demonstrated higher satisfaction regarding efficacy, independency, and comfort with IPV than with other airway clearance techniques. This was not related to the time required for the treatment. This benefit was not found in another study in which IPV was compared with HFCWC or postural drainage with percussion.

Adverse Effects and Drop-Outs in COPD, CF, and Bronchiectasis. Few adverse effects related to IPV were mentioned in the different studies. In subjects with COPD, 2 studies revealed complications or discomfort. Even though some subjects were intubated after inclusion in 1 study, it was not related to IPV. In another study, 2 subjects did not tolerate settings with a higher frequency of percussions (1.220 cm H$_2$O-350 c/min and 1.840 cm H$_2$O-350 c/min).

One study observed mild hemoptysis associated with a Pseudomonas aeruginosa infection in 1 subject with CF. Two drop-outs were noted in 3 studies in subjects with CF and 8 others without detailed reasons. The number of drop-outs were not different in the IPV group. Minor adverse effects were also found in 27% of subjects with bronchiectasis.

Discussion

This systematic review highlights that IPV provides insufficient and heterogeneous results, which precludes IPV from being routinely recommended for different chronic obstructive airway diseases. In subjects with stable COPD, there is a lack of evidence regarding the use of IPV. However, during exacerbation, IPV may improve gas exchange and reduce hospital length of stay. In patients with CF or bronchiectasis, the efficacy of IPV has not been demonstrated.

Studies evaluating IPV as an airway clearance technique investigated mainly 2 diseases at the time of the systematic review (CF and COPD). Only 1 study focused on bronchiectasis. Compared to the total number of publications regarding airway clearance in these specific diseases, IPV is poorly studied. Combined with poor statistical power, the internal and external validity of the reviewed studies explain why IPV lacks evidence as an effective airway clearance technique in chronic obstructive airway disease, and it is difficult to draw robust conclusions.

We observed broad heterogeneity in the protocols of the studies related to the use of IPV in chronic obstructive airway diseases. The studies considered 6 different airway clearance techniques as comparators, and 3 of the studies used techniques that are not recognized as airway clearance techniques (NIV and nebulization). With regard to the inclusion and exclusion criteria of the studies,
few adverse events were noted in the reviewed studies. The risk of hemoptysis is the main adverse effect to be considered, and this was observed only in subjects with CF.

The settings were heterogeneous even though all of the studies used at least 1 setting based on a low frequency, which is consistent with findings related to the specific settings to promote the clearance of lung secretions. Indeed, it is well demonstrated that adapting the settings for IPV modifies the resulting effects on the lungs. Surprisingly, while the inspiratory/expiratory time ratio seems to be an essential setting to promote mobilization of sputum, this parameter was rarely mentioned in the protocols.

Contrary to subjects with CF, subjects with COPD were mainly investigated during exacerbation in the retrieved studies. This is explained by the difference in the respective objectives of the IPV in both diseases. In patients with CF, the main objective is to clear secretions, whereas in patients with COPD, IPV targets an improvement of gas exchange and the parameters related to the exacerbations. IPV is probably more effective as a ventilator support method than an airway clearance technique in COPD.

IPV demonstrated immediate and prolonged effects on peripheral oxygen saturation and gas exchange both in stable subjects with COPD and during exacerbations. These effects highlight possible lung recruitment obtained by this technique. A similar effect was found in subjects with atelectasis and obesity. This could be partly due to the positive pressure generated by IPV and to the improvement in lung ventilation. We could hypothesize that improved airway clearance also contributes to this result. However, even though other studies showed a greater expectorated sputum amount with different airway clearance techniques in COPD, this was not verified in this systematic review when focusing exclusively on IPV.

During exacerbation, a promising benefit was observed in 2 studies on the length of hospital stay. Such an effect was rarely found in studies related to airway clearance techniques in COPD. This immediate effect was surprising. The principal aim of airway clearance techniques is to improve the elimination of sputum. Thus, we could hypothesize that reducing sputum in the lungs would improve vital capacity. However, even though a recent study in bronchiectasis observed such an effect, it was rarely found with other airway clearance techniques in subjects with CF. In this systematic review, we did not find any benefit of IPV on airway clearance, contrary to what was demonstrated in subjects with Duchenne muscular dystrophy. The wet weight of sputum increased with IPV compared to other airway clearance techniques in a study including 3 daily sessions, but the combination of IPV and autologous drainage was as efficient on sputum as autologous drainage used alone. The immediate benefit observed on wet weight was probably explained by normal saline delivered simultaneously with IPV because the dry weight of sputum was not different in the same study. Moreover, cold and dry air delivered to the lungs by the phasitron may cause mucus on the respiratory epithelium to become more viscous due to insufficient moisture carried by cold air. Indeed, the isothermic saturation boundary moves distally when cold and dry gases are inhaled because a greater proportion of the airways have to participate in heat and moisture exchange.

During IPV, a greater amount of water evaporates from the mucus to improve the humidification of the dry and cold gas. This is particularly important when the nose is bypassed, and this effect likely affects airway clearance negatively. The nebulizer provided with the IPV device is insufficient to promote adequate humidification, so a heated humidifier on the inspiratory line downstream is required. We can also assume that the amount of secretions in the lung at the time of the session influences the airway clearance effect related to IPV, as Toussaint et al clearly demonstrated in neuromuscular subjects. The considerable inter-subject variability in the recovered sputum as illustrated by coefficients of variation > 100% in the sputum wet weight reinforces this hypothesis. It is not surprising that inspiratory and expiratory muscle strength does not seem to be improved by the adjuction of IPV during a pulmonary rehabilitation program. We postulated that it could be more interesting to analyze other outcomes such as gas exchange in subjects with severe CF. Moreover, the effect of IPV on early obstructive lung disease, early disease progression, and ventilation heterogeneity could be investigated in terms of lung clearance index in patients with CF. Indeed, the benefit of IPV in patients with CF could be related to the positive airway pressure generated by the device, similarly to the ventilator support offered by IPV in patients with COPD.

In this systematic review, 2 studies delivered bronchodilators by nebulization with IPV. This was surprising due to the evidence of poor efficiency of this delivery method in spontaneously breathing subjects. However,
the concerned studies were performed previous to these findings.

The main limitation of this systematic review was the broad heterogeneity of the results and settings in the reviewed studies. This is a common limitation regarding airway clearance techniques. The small number of subjects included in this systematic review limits the external validity of these studies. Moreover, the reviewed studies were performed in subjects experiencing acute or chronic conditions, and investigated immediate or prolonged effects. The lack of evidence for IPV is due largely to the absence of standardized protocols and the difficulty of finding an outcome to evaluate the efficacy of the technique. Moreover, many studies are underpowered as illustrated by low Downs and Black scores. Further studies on large and homogeneous samples of subjects, with standardized protocols (fixed settings) in the different disease states, are needed. The way to use IPV in each specific condition should be established, depending on the physiological effects. Indeed, Fornasa et al demonstrated that the chosen frequency influences the pressure and the flow generated by IPV. Similar studies should be performed to better understand the impact of the different settings.

Conclusions

In conclusion, the systematic use of IPV in different chronic obstructive airway diseases as an airway clearance technique is not supported by sufficiently strong evidence to recommend its routine use. However, IPV could offer some benefits in patients with COPD during exacerbation by improving gas exchange and by possibly reducing the length of hospital stay. IPV is probably more a ventilatory support method than an airway clearance technique in these patients. In CF, even if the subjects mentioned a higher satisfaction regarding efficacy, independency, and comfort with IPV, its routine use cannot be supported. Further studies are required, particularly in patients with CF, to evaluate IPV as a tool for airway clearance but also for improving early obstructive lung disease and lung ventilation heterogeneity in patients with CF or bronchiectasis. Moreover, patients with COPD in a stable condition should be better investigated.

REFERENCES


